check_circleStudy Completed

Lymphoma, Non-Hodgkin

Safety and tolerability of BAY1862864 Injection in subjects with relapsed or refractory CD22-positive non-Hodgkin’s lymphoma

Trial purpose

To establish a recommended dose of BAY1862864 Injection and to investigate how the study drug acts in the body, on the cancer cells and how safe it is in patients with advanced non-Hodgkin’s lymphoma (NHL)

Key Participants Requirements

Sex

Both

Age

18 - N/A

Trial summary

Enrollment Goal
21
Trial Dates
November 2015 - November 2019
Phase
Phase 1
Could I Receive a placebo
No
Products
BAY1862864
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Southampton General HospitalSouthampton, SO16 6YD, United Kingdom
Completed
Royal Free HospitalLondon, NW3 2QG, United Kingdom
Completed
Skanes UniversitetssjukhusLund, 221 85, Sweden
Completed
Royal Marsden NHS Trust (Surrey)Sutton, SM2 5PT, United Kingdom

Primary Outcome

  • Maximum tolerated dose assessed by the number of subjects with dose-limiting toxicities (DLTs)
    date_rangeTime Frame:
    Up to 6 weeks
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

An open-label phase I, dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, biodistribution, radiation dosimetry and pharmacokinetics of BAY1862864 Injection in subjects with relapsed or refractory CD22-positive non-Hodgkin’s lymphoma
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Non-randomized
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
5